Frontiers in Pharmacology (Jul 2019)

Novel Peptide Conjugates of Modified Oligonucleotides for Inhibition of Bacterial RNase P

  • Darya Novopashina,
  • Darya Novopashina,
  • Mariya Vorobyeva,
  • Anton Nazarov,
  • Anna Davydova,
  • Nikolay Danilin,
  • Lyudmila Koroleva,
  • Lyudmila Koroleva,
  • Andrey Matveev,
  • Alevtina Bardasheva,
  • Nina Tikunova,
  • Nina Tikunova,
  • Maxim Kupryushkin,
  • Dmitrii Pyshnyi,
  • Dmitrii Pyshnyi,
  • Sidney Altman,
  • Sidney Altman,
  • Alya Venyaminova

DOI
https://doi.org/10.3389/fphar.2019.00813
Journal volume & issue
Vol. 10

Abstract

Read online

Novel alternatives to traditional antibiotics are now of great demand for the successful treatment of microbial infections. Here, we present the engineering and properties of new oligonucleotide inhibitors of RNase P, an essential bacterial enzyme. The series of 2’-O-methyl RNA (2’-OMe-RNA) and phosphoryl guanidine oligonucleotides were targeted to the substrate-binding region of M1 RNA subunit of the RNase P. Uniformly modified 2’-OMe RNA and selectively modified phosphoryl guanidine oligonucleotides possessed good stability in biological media and effectively inhibited RNase P. Their conjugates with transporting peptides were shown to penetrate bacterial cells (Escherichia coli and Acinetobacter baumannii) and inhibit bacterial growth.

Keywords